Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
GILD
Gilead Sciences
$116.20
Chart
$108.91 (+6.69%)
$104.53 (+11.16%)
$116.04 (+0.14%)
$77.73 (+49.49%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
GILD
Gilead Sciences
Current Price
$116.20
Strong Buy
Login to view Gilead Sciences (GILD) recommendation from the last 90 days from financial news and social media.
Chart
$108.91 (+6.69%)
$104.53 (+11.16%)
$116.04 (+0.14%)
$77.73 (+49.49%)
GILD Latest Analysis
Nasdaq 100 Movers: CHTR GILD. In early trading on Friday shares of Gilead Sciences topped the list of the days best performing components of the Nasdaq 100 index trading up 2.9%. Year to date Gilead Sciences registers a 26.1% gain.And the worst performing Nasdaq 100 component thus far on the day is C
Today
Gileads Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales. In June the United States Food and Drug Administration (FDA) approved) Yeztugo(lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg making it the first and only twice-yearly option available in the United States for people.Data show that ≥99.9% of participants who received Yeztugo in the Phase 3 PURPOSE 1 and PURPOSE 2 trials r
Today
Gilead upgraded to Buy at Needham on new HIV drug.
Today
This Gilead Sciences Analyst Turns ish. Here Are Top 5 Upgrades For Friday. Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes including upgrades downgrades and initiations please see our analyst ratings page.Needham analyst Joseph Stringer upgraded the rating for ) from Hold to Buy and announced a $133 price target. Gilead Sciences shares closed at $113.20 on Thursday. See how other analysts view this stock.Mizuho analyst Dan Dol
Today
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention. MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527 aiming to rival Gileads daily PrEP options.
Tue Jul 15, 2025
Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations.
Tue Jul 15, 2025
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today. Gilead Sciences (NASDAQ:) has outperformed the market over the past 15 years by 1.24% on an annualized basis producing an average annual return of 13.62%. Currently Gilead Sciences has a market capitalization of $139.43 billion.
Mon Jul 14, 2025
Gilead twice-yearly HIV prevention drug Yeztugo recommended by WHO.
Mon Jul 14, 2025
Gileads Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million. ) on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS Tuberculosis and Malaria to supply lenacapavir — Gilead’.s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as .Through the agreement Gilead will supply enough doses to reach up to two million people over three years in countries supported by the Global Fund at no profit to Gilea
Wed Jul 9, 2025
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet. Based on the average brokerage recommendation (ABR) Gilead (GILD) should be added to ones portfolio. Wall Street analysts overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So is the stock worth buying?
Wed Jul 9, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
GILD Stock trends
GILD Stock performance
GILD Stock analysis
GILD investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Latest Updates
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings